
Bioequivalence of Levothyroxine Preparations: Industry Sponsorship and Academic Freedom-Reply
Betty J. Dong, PharmD;
John G. Gambertoglio, PharmD;
Lauren Gee, MPH;
Francis S. Greenspan, MD
University of California, San Francisco
Walter W. Hauck, PhD
Thomas Jefferson University Philadelphia, Pa
John R. White
Washington State University Spokane
Jeff L. Bubp
San Mateo County General Hospital San Mateo, Calif
JAMA. 1997;277(15):1200-1201.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
In Reply.
—We appreciate the comments by Mr Eckert to clarify and defend Knoll's action to date, although some of the study chronology is in error. We are delighted at the prospect of finally being able to publish our findings. We have tried our best to cooperate with Knoll even though we believed their concerns to be unjustified. We found it impossible to comply with many of their requests because to do so would have intentionally altered our study findings.
We are pleased that Knoll now recognizes the importance of academic freedom, the peer review process, and the need to allow scientific debate to occur.
This unfortunate incident has illuminated the fragile relationship that could exist between a sponsor and investigators when the results of a study are not as anticipated. The difficult, sobering, and painful lessons learned should be remembered by all when collaborations between industry and academia occur. We know
. . . [Full Text PDF of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|